Hi-Tech Pharmacal (HITK) Slammed On Generic Flonase Competition
Tweet
Share
E-mailGet Alerts HITK Hot Sheet
Join SI Premium – FREE
Shares of Hi-Tech Pharmacal (Nasdaq: HITK) are under heavy pressure Tuesday which could be related to news that Wockhardt received final FDA approval for generic Flonase. This could be viewed as negative as Hi-Tech has its own generic-version of Flonase.
Shares of Hi-Tech are down 18 percent to $34.38 currently.
Shares of Hi-Tech are down 18 percent to $34.38 currently.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enhertu shows 14.3-month PFS in first-line lung cancer trial
- Paramout settlement talks will be in late October, judge says
- Zipalertinib combo shows 6-month PFS gain in lung cancer trial
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
